These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 26628458)

  • 21. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model.
    Wahl A; Ho PT; Denton PW; Garrett KL; Hudgens MG; Swartz G; O'Neill C; Veronese F; Kashuba AD; Garcia JV
    Sci Rep; 2017 Feb; 7():41098. PubMed ID: 28145472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing the Benefits of HIV Preexposure Prophylaxis.
    Buchbinder SP
    Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Offering pre-exposure prophylaxis for HIV prevention to pregnant and postpartum women: a clinical approach.
    Seidman DL; Weber S; Cohan D
    J Int AIDS Soc; 2017 Mar; 20(Suppl 1):21295. PubMed ID: 28361503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis.
    Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P
    HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New PrEP formulation approved…but only for some.
    The Lancet Hiv
    Lancet HIV; 2019 Nov; 6(11):e723. PubMed ID: 31672278
    [No Abstract]   [Full Text] [Related]  

  • 26. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839
    [No Abstract]   [Full Text] [Related]  

  • 28. Successful Implementation of HIV Preexposure Prophylaxis: Lessons Learned From Three Clinical Settings.
    Marcus JL; Volk JE; Pinder J; Liu AY; Bacon O; Hare CB; Cohen SE
    Curr HIV/AIDS Rep; 2016 Apr; 13(2):116-24. PubMed ID: 26898645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
    Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
    J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
    Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
    AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ending sexual HIV transmission: lessons learned from perinatal HIV.
    Weber S; Grant RM
    J Assoc Nurses AIDS Care; 2015; 26(5):520-5. PubMed ID: 26096627
    [No Abstract]   [Full Text] [Related]  

  • 32. Where next with preexposure prophylaxis?
    Nugent D; Gilson R
    Curr Opin Infect Dis; 2017 Feb; 30(1):44-49. PubMed ID: 27870645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of circulating resistance-associated mutations on HIV pre-exposure prophylaxis (PrEP) efficacy: Modeling from antiretroviral resistance cohort analysis (ARCA) national database.
    Rossotti R; Borghi V; Callegaro AP; Micheli V; Bruzzone B; Colao G; Gismondo MR; Vicenti I; Penco G; Zazzi M; Rusconi S
    J Clin Virol; 2016 Oct; 83():48-53. PubMed ID: 27591555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low willingness and actual uptake of pre-exposure prophylaxis for HIV-1 prevention among men who have sex with men in Shanghai, China.
    Ding Y; Yan H; Ning Z; Cai X; Yang Y; Pan R; Zhou Y; Zheng H; Gao M; Rou K; Wu Z; He N
    Biosci Trends; 2016 May; 10(2):113-9. PubMed ID: 27052151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.
    Zablotska IB; Selvey C; Guy R; Price K; Holden J; Schmidt HM; McNulty A; Smith D; Jin F; Amin J; Cooper DA; Grulich AE;
    BMC Public Health; 2018 Feb; 18(1):210. PubMed ID: 29394918
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
    Mayor S
    BMJ; 2015 Sep; 351():h4860. PubMed ID: 26359448
    [No Abstract]   [Full Text] [Related]  

  • 37. Genital Immune Cell Activation and Tenofovir Gel Efficacy: A Case-Control Study.
    Liebenberg LJP; Passmore JAS; Osman F; Jewanraj J; Mtshali A; Garcia-Lerma JG; Heneine W; Holder A; Archary D; Ngcapu S; Sivro A; Mansoor LE; Abdool Karim Q; Abdool Karim SS; McKinnon LR
    Clin Infect Dis; 2022 Sep; 75(6):1088-1091. PubMed ID: 35142337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis.
    Haaland RE; Martin A; Holder A; Fountain JJ; Hall L; Pescatore NA; Heeke S; Kelley CF
    AIDS; 2017 Jul; 31(11):1647-1650. PubMed ID: 28657968
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
    Mugwanya KK; Baeten JM
    Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. On-demand PrEP efficacy: forgiveness or timely dosing.
    Parienti JJ
    Lancet HIV; 2020 Feb; 7(2):e79-e80. PubMed ID: 31784344
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.